Arlington Capital Partners Announces Acquisitions of Thortex and Millennium Surgical by Avalign Technologies

WASHINGTON–(BUSINESS WIRE)–Avalign Technologies (“Avalign”), a portfolio company of Arlington
Capital Partners (“Arlington Capital”), has completed the acquisitions
of Thortex and Millennium Surgical (“Millennium”).

Thortex is a leading provider of proprietary porous coatings and metal
injection molding as well precision manufacturing solutions to the
medical device market. Thortex is one of the only companies in the world
able to provide porous coating solutions for titanium and cobalt-chrome
orthopedic implants. In addition, Thortex provides a full suite of
manufacturing and engineering technologies including metal injection
molding, CNC machining, finishing and assembly to medical device OEMs.

Millennium is a provider of specialty surgical instruments focused on
delivering difficult-to-find instruments utilizing innovative,
e-cataloging, web-based marketing tools, and technical sales support.
Millennium offers more than 17,000 branded SKUs across a variety of
clinical areas including neurosurgery, ophthalmics and orthopedics to a
diverse array of hospital and ambulatory surgical center customers.

Matt Altman, a Managing Partner at Arlington Capital said, “The
incorporation of Thortex and Millennium into the Avalign platform adds
new and proprietary capabilities which enhance Avalign’s strategic
position in the marketplace. The increased scale and breadth of services
and technologies provided by these acquisitions will accrue to the
benefit of Avalign’s customers and bolster Avalign’s already impressive

“Thortex and Millennium nicely complement and expand the manufacturing
technologies and services that Avalign offers and provide us with the
ability to continue gaining share with our customers,” said Forrest
Whittaker, CEO of Avalign Technologies. “We are excited to welcome the
Thortex and Millennium teams to the Avalign family, and thankful for
Arlington’s support in consummating these highly strategic acquisitions.”

Malcolm Little, a Principal at Arlington Capital, added: “The
proprietary technologies developed by both Thortex and Millennium
represent truly unique offerings in the market. We are pleased to
complete these acquisitions and continue to pursue additional
opportunities to strategically scale our business.”

About Avalign Technologies

Avalign Technologies, Inc. (“Avalign”) is a leading provider of
proprietary coatings and full-service precision manufacturer of
implants, specialty instrumentation, cutting instruments, and delivery
systems to the orthopedic medical device and specialty surgical markets.
Avalign offers its OEM partners a broad portfolio of manufacturing
technologies and coating solutions as well as extensive engineering
design, development, and project management capabilities from concept to
launch. Avalign has an established reputation for consistent and
sophisticated quality systems, flexible capacity capabilities,
innovative proprietary manufacturing technologies, unmatched product
offering, and superior customer service.

About Arlington Capital Partners

Arlington Capital Partners is a Washington, D.C.-area private equity
firm that has managed $2.2 billion of committed capital via four
investment funds, including Arlington’s fourth and most recent $700
million fund. Arlington is focused on middle market investment
opportunities in growth industries including: healthcare,
aerospace/defense, government services and technology and business
services and software. The firm’s professionals and network have a
unique combination of operating and private equity experience that
enables Arlington to be a value-added investor. Arlington invests in
companies in partnership with high quality management teams that are
motivated to establish and/or advance their company’s position as
leading competitors in their field.


Arlington Capital Partners
Matt Altman or Malcolm Little
Wisconsin Avenue, Suite 200
Chevy Chase, MD 20815